Flagship Harbor Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-10,350
| Closed | -$60.4K | – | 659 |
|
|
2022
Q4 | $60.4K | Hold |
10,350
| – | – | 0.01% | 591 |
|
|
2022
Q3 | $69K | Sell |
10,350
-50
| -0.5% | -$303 | 0.01% | 572 |
|
|
2022
Q2 | $44K | Hold |
10,400
| – | – | ﹤0.01% | 583 |
|
|
2022
Q1 | $35K | Hold |
10,400
| – | – | ﹤0.01% | 612 |
|
|
2021
Q4 | $33K | Sell |
10,400
-3,500
| -25% | -$11.6K | ﹤0.01% | 640 |
|
|
2021
Q3 | $59K | Hold |
13,900
| – | – | 0.01% | 619 |
|
|
2021
Q2 | $59K | Buy |
13,900
+2,500
| +22% | +$10.6K | 0.01% | 623 |
|
|
2021
Q1 | $57K | Buy |
+11,400
| New | +$92.1K | 0.01% | 613 |
|
|
2020
Q4 | – | Sell |
-4,000
| Closed | -$39K | – | 1906 |
|
|
2020
Q3 | $39K | Hold |
4,000
| – | – | 0.01% | 935 |
|
|
2020
Q2 | $39K | Sell |
4,000
-400
| -9% | -$3.84K | 0.01% | 927 |
|
|
2020
Q1 | $39K | Sell |
4,400
-600
| -12% | -$5.92K | 0.01% | 827 |
|
|
2019
Q4 | $46K | Hold |
5,000
| – | – | 0.01% | 847 |
|
|
2019
Q3 | $29K | Buy |
5,000
+3,100
| +163% | +$32.9K | 0.01% | 961 |
|
|
2019
Q2 | $22K | Hold |
1,900
| – | – | ﹤0.01% | 1045 |
|
|
2019
Q1 | $22K | Hold |
1,900
| – | – | ﹤0.01% | 1037 |
|
|
2018
Q4 | $23K | Hold |
1,900
| – | – | 0.01% | 966 |
|
|
2018
Q3 | $27K | Hold |
1,900
| – | – | 0.01% | 1025 |
|
|
2018
Q2 | $31K | Buy |
+1,900
| New | +$36.9K | 0.01% | 957 |
|
Flagship Harbor Advisors's CNCE Position: Q1 2023 in Review
Flagship Harbor Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 10,350 shares — an estimated $60.4K sold.
Flagship Harbor Advisors first reported a position in CNCE in Q2 2018 and held it in 18 quarters. The position peaked at $69K in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Flagship Harbor Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Flagship Harbor Advisors sold 10,350 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $60.4K.
- Flagship Harbor Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q2 2018 and held it in 18 quarters.
- Flagship Harbor Advisors's Concert Pharmaceuticals, Inc. position peaked at $69K in Q3 2022.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Flagship Harbor Advisors's 13F filing for Q1 2023, filed 12 Apr 2023.